Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

EANS-News: SYGNIS Pharma AG
SYGNIS strengthens patent position on AX200 for the treatment of neurodegenerative diseases

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Licensing Agreements
SYGNIS strengthens patent position on AX200
for the treatment of neurodegenerative diseases
Heidelberg,  09  February  2011  -  SYGNIS  Pharma  AG  (Frankfurt:  
LIOK;  ISIN DE000A1E9B74; Prime Standard),  a  clinical  stage  
biotech  company  developing innovative therapies for the  treatment 
of  neurodegenerative  diseases,  today announced that it has 
licensed the exclusive rights to a European patent,  which will 
significantly expand SYGNIS´ IP-position with regard to its lead  
candidate AX200. AX200, which is known as the G-CSF protein, is 
currently  in  a  clinical phase II efficacy trial for the treatment 
of acute ischemic stroke (AXIS 2).
The licence covers an issued patent which provides broad protection 
with  regard to the use of  G-CSF  for  the  reorganisation  of  
neural  tissue  affected  by neurodegenerative diseases, especially  
stroke  or  trauma.  The  patent  rights strengthen SYGNIS´ 
IP-position around AX200 in  the  current  AXIS  2-trial  and also 
cover the use  of  G-CSF  for  the  treatment  of  patients  in  the 
early rehabilitation-phase following a stroke. The patent has a 
scheduled expiry  date of  2022,  not  including  any  potential  
extensions.  In  this   respect,   it complements the patent, granted
in Europe in  2006  and  in  the  USA  in  2009, covering  the  use  
of  AX200  for  the  treatment  of  stroke  by   stimulating 
arteriogenesis, to which SYGNIS has exclusive access under a  license
agreement with the Max-Planck Gesellschaft.
Dr Frank Rathgeb, Chief  Medical  Officer  of  SYGNIS,  said:  "These
exclusive patent rights  further  strengthen  the  significant  
therapeutic  potential  of AX200. The current phase II efficacy trial
for the treatment of  acute  ischemic stroke is progressing well and 
we expect to report  the  top-line  data  in  the second half of 
2011. Our robust intellectual property position means we  are  in a 
strong position to maximise the market potential of AX200."
About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,  
is  a  specialty  pharmaceutical company listed on the Prime Standard
of the German stock exchange.  The  Company is focused on the 
research and  development  of  innovative  therapies  for  the 
treatment of disorders of the Central Nervous System. SYGNIS´ core 
projects  are currently Acute Stroke for which SYGNIS´ lead clinical 
programme  is  AX200  as well as the preclinical KIBRA-project for 
the treatment of  different  forms  of dementia. All these disorders 
are  characterized  by  the  fact  that,  as  the disease progresses,
nerve cells are damaged and die.  Although  there  is  great medical 
demand, there are currently no  or  only  inadequate  treatment  
options available. SYGNIS´ strategy for growth includes the 
development of new  products from its own research and through 
in-licensing and acquisitions.
For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812 
franz-werner.haas@sygnis.de
Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187
### Disclaimer Some statements included in this  press  release,  
relating  neither  to  proven financial results nor other  historical
data,  should  be  viewed  as  forward- looking, i.e. not definite. 
Such statements are  mainly  predictions  of  future results, trends,
plans or goals. These statements should not  be  considered  to be 
total guarantees since given their very nature they are subject to 
known  and unknown risks and imponderability and can be affected  by 
other  factors  as  a consequence of which the actual results, plans 
and goals  of  SYGNIS  Pharma  AG may deviate greatly from the  
established  conclusions  or  implied  predictions contained in such 
statements. SYGNIS does not undertake to  publicly  update  or revise
these statements in the light of new information  or  future  results
or for any other reason.  ###
end of announcement                               euro adhoc

Contact:

Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE000A1E9B74
WKN: A1E9B7
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG